share_log

EF Hutton Initiates Coverage On Bone Biologics With Buy Rating, Announces Price Target of $2.25

Benzinga Real-time News ·  Oct 18, 2022 07:48

EF Hutton analyst Constantine Davides initiates coverage on Bone Biologics (NASDAQ:BBLG) with a Buy rating and announces Price Target of $2.25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment